Universe Pharmaceuticals INC (UPC) stock forecast & analysis
1.51
NasdaqCM · USDDelayed by 15 minutes
Down: -0.02, -1.3%
1 analysis
- Open
- 1.48
- Previous close
- 1.53
- Day range
- 1.47 – 1.58
- 52-week range
- 1.33 – 17.96
- Volume (shares)
- 12.84K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 5.01M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.85
- Market cap
- 7.59M
Market Scanner’s AI analysis of Universe Pharmaceuticals INC (UPC), updated June 2026: UPC's recent analysis covered a significant acquisition, extreme technical overbought conditions, and declining revenue.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Universe Pharmaceuticals INC (UPC) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
UPC's recent analysis covered a significant acquisition, extreme technical overbought conditions, and declining revenue.
Recent analyses for UPC focused on a major acquisition of Best Praise International, which drove a substantial after-hours price surge. This was juxtaposed with technical indicators showing extreme overbought conditions and a moderate volatility. Fundamentally, the company reported declining year-over-year quarterly revenue and negative profitability metrics.
Factors discussed — upside
- Retail investor sentiment on StockTwits shows a predominantly bullish lean.
- Significant price surge of 288% after hours linked to acquisition news.
- MACD indicates bullish momentum.
- RSI and MFI show strong upward momentum and buying pressure.
Factors discussed — risks
- Year-over-year quarterly revenue decline of 14.1%.
- Deeply negative TTM profit margin (-20.562%), operating margin (-6.767%), and return on equity (-7.226%).
- Extremely overbought conditions indicated by RSI and MFI.
- Stock trading below its 50-day and 200-day moving averages.
- Acquisition impact
- Technical indicators
- Revenue trends
- Profitability metrics
Summary updated .
UPC technical indicators
Common technical indicators for UPC, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.54 | Price below |
| 10-day exponential moving average | 1.68 | Price below |
| Relative strength index (14-day) | 26.87 | Oversold |
| MACD line (12/26/9) | -0.6795 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.08 – 4.45 | Price inside the bands |
Frequently asked questions
- What is the bull case for Universe Pharmaceuticals INC?
- The bull case for UPC centers on strong upward momentum indicated by technical indicators like the MACD, RSI, and MFI, alongside predominantly bullish retail investor sentiment. A significant after-hours price surge following the announcement of an acquisition of Best Praise International also contributed to the positive outlook.
- What are the risks for Universe Pharmaceuticals INC?
- Risks for UPC include a year-over-year quarterly revenue decline and deeply negative profitability metrics, such as TTM profit margin and operating margin. The company's stock is also trading below its longer-term moving averages, and technical indicators show extremely overbought conditions.
- Is Universe Pharmaceuticals INC bullish or bearish?
- Recent AI analyses of Universe Pharmaceuticals INC examined factors on both sides. Discussed upside: The bull case for UPC centers on strong upward momentum indicated by technical indicators like the MACD, RSI, and MFI, alongside predominantly bullish retail investor sentiment. A significant after-hours price surge following the announcement of an acquisition of Best Praise International also contributed to the positive outlook. Discussed risks: Risks for UPC include a year-over-year quarterly revenue decline and deeply negative profitability metrics, such as TTM profit margin and operating margin. The company's stock is also trading below its longer-term moving averages, and technical indicators show extremely overbought conditions. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Universe Pharmaceuticals INC?
- Recent analyses for UPC focused on a major acquisition of Best Praise International, which drove a substantial after-hours price surge. This was juxtaposed with technical indicators showing extreme overbought conditions and a moderate volatility. Fundamentally, the company reported declining year-over-year quarterly revenue and negative profitability metrics.
- How does Market Scanner analyse Universe Pharmaceuticals INC?
- Every analysis of Universe Pharmaceuticals INC runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Universe Pharmaceuticals INC?
The bull case for UPC centers on strong upward momentum indicated by technical indicators like the MACD, RSI, and MFI, alongside predominantly bullish retail investor sentiment. A significant after-hours price surge following the announcement of an acquisition of Best Praise International also contributed to the positive outlook.
What are the risks for Universe Pharmaceuticals INC?
Risks for UPC include a year-over-year quarterly revenue decline and deeply negative profitability metrics, such as TTM profit margin and operating margin. The company's stock is also trading below its longer-term moving averages, and technical indicators show extremely overbought conditions.
Is Universe Pharmaceuticals INC bullish or bearish?
Recent AI analyses of Universe Pharmaceuticals INC examined factors on both sides. Discussed upside: The bull case for UPC centers on strong upward momentum indicated by technical indicators like the MACD, RSI, and MFI, alongside predominantly bullish retail investor sentiment. A significant after-hours price surge following the announcement of an acquisition of Best Praise International also contributed to the positive outlook. Discussed risks: Risks for UPC include a year-over-year quarterly revenue decline and deeply negative profitability metrics, such as TTM profit margin and operating margin. The company's stock is also trading below its longer-term moving averages, and technical indicators show extremely overbought conditions. These are descriptive observations, not a recommendation.
What is the latest sentiment on Universe Pharmaceuticals INC?
Recent analyses for UPC focused on a major acquisition of Best Praise International, which drove a substantial after-hours price surge. This was juxtaposed with technical indicators showing extreme overbought conditions and a moderate volatility. Fundamentally, the company reported declining year-over-year quarterly revenue and negative profitability metrics.
How does Market Scanner analyse Universe Pharmaceuticals INC?
Every analysis of Universe Pharmaceuticals INC runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh UPC analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.